121 related articles for article (PubMed ID: 27347207)
1. Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2.
Martín AJ; Alfonso PG; Rupérez AB; Jiménez MM
Oncol Lett; 2016 Jul; 12(1):727-730. PubMed ID: 27347207
[TBL] [Abstract][Full Text] [Related]
2. A Near-Complete Response to Treatment with Gemcitabine plus nab (®)-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report.
Shakir AR
Case Rep Oncol; 2014 Sep; 7(3):711-7. PubMed ID: 25493084
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Sohal DP; Mangu PB; Khorana AA; Shah MA; Philip PA; O'Reilly EM; Uronis HE; Ramanathan RK; Crane CH; Engebretson A; Ruggiero JT; Copur MS; Lau M; Urba S; Laheru D
J Clin Oncol; 2016 Aug; 34(23):2784-96. PubMed ID: 27247222
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting.
Cartwright TH; Parisi M; Espirito JL; Wilson TW; Pelletier C; Patel M; Babiker HM
Drugs Real World Outcomes; 2018 Sep; 5(3):149-159. PubMed ID: 29946913
[TBL] [Abstract][Full Text] [Related]
5.
Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study.
Saito K; Michihata N; Hamada T; Jo T; Matsui H; Fushimi K; Nakai Y; Yasunaga H; Fujishiro M
Cancer Sci; 2023 Oct; 114(10):3996-4005. PubMed ID: 37547944
[TBL] [Abstract][Full Text] [Related]
7. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma.
Neuzillet C; Babai S; Kempf E; Pujol G; Rousseau B; Le-Louët H; Christophe Tournigand
Medicine (Baltimore); 2016 Jun; 95(26):e4006. PubMed ID: 27368013
[TBL] [Abstract][Full Text] [Related]
8. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age.
Petrillo A; Pappalardo A; Calabrese F; Tirino G; Pompella L; Ventriglia J; Laterza MM; Caterino M; Sforza V; Iranzo V; Biglietto M; Orditura M; Ciardiello F; Conzo G; Molino C; De Vita F
J Gastrointest Oncol; 2019 Oct; 10(5):910-917. PubMed ID: 31602329
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and safety of
Mudad R; Patel MB; Margunato-Debay S; Garofalo D; Lal LS
Lung Cancer (Auckl); 2017; 8():179-190. PubMed ID: 29089791
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and resource utilization of
Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
[TBL] [Abstract][Full Text] [Related]
11. Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer.
Picozzi V; Narayanan S; Henry Hu X; Vacirca J
J Gastrointest Cancer; 2017 Mar; 48(1):103-109. PubMed ID: 28028766
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma.
Zong Y; Peng Z; Wang X; Lu M; Shen L; Zhou J
Cancer Manag Res; 2020; 12():12657-12666. PubMed ID: 33328763
[TBL] [Abstract][Full Text] [Related]
13. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.
Yang SH; Guo JC; Hsu C; Kuo SH; Tien YW; Cheng AL; Yeh KH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):97-105. PubMed ID: 30852003
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer.
Al-Hajeili M; Azmi AS; Choi M
Onco Targets Ther; 2014; 7():187-92. PubMed ID: 24523592
[TBL] [Abstract][Full Text] [Related]
15. Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report.
Comito F; Grassi E; Poerio A; Freier E; Calculli L; Zompatori M; Ricci C; Casadei R; Di Marco M
BJR Case Rep; 2018; 4(2):20170086. PubMed ID: 30363157
[TBL] [Abstract][Full Text] [Related]
16. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.
Ahn DH; Krishna K; Blazer M; Reardon J; Wei L; Wu C; Ciombor KK; Noonan AM; Mikhail S; Bekaii-Saab T
Ther Adv Med Oncol; 2017 Feb; 9(2):75-82. PubMed ID: 28203300
[TBL] [Abstract][Full Text] [Related]
17. First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy
Han SY; Kim DU; Seol YM; Kim S; Lee NK; Hong SB; Seo HI
World J Clin Cases; 2020 Sep; 8(18):4022-4033. PubMed ID: 33024759
[TBL] [Abstract][Full Text] [Related]
18. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
Kieler M; Unseld M; Bianconi D; Schindl M; Kornek GV; Scheithauer W; Prager GW
J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121198
[TBL] [Abstract][Full Text] [Related]
19. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer.
Han SY; Kim DU; Seol YM; Kim S; Lee NK; Hong SB; Seo HI
World J Clin Cases; 2020 Sep; 8(17):3718-3729. PubMed ID: 32953848
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.
Zhang Y; Hochster H; Stein S; Lacy J
Exp Hematol Oncol; 2015; 4():29. PubMed ID: 26451276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
